Table 2.
Glucose-lowering medication in patients of COVID-19 with T2DM.
| Glucose-lowering medication | Case (%) |
|---|---|
| Metformin | 12 (16.90%) |
| Insulin | 7 (9.86%) |
| Acarbose | 6 (8.45%) |
| SGLT2-I∗ | 2 (2.82%) |
| Pioglitazone | 1 (1.41%) |
∗SGLT2: sodium-dependent glucose transporters 2 inhibitors.